CORT
Corcept TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bull case is that March 2026 approval converted ROSELLA from a trial story into a launch story, and the April 2026 full data package strengthened confidence that Lifyorli can become a meaningful ovarian-cancer franchise. Corcept also retains a profitable base business, 2026 revenue guidance of $900-$1,000 million, and $532.4 million of cash, cash equivalents and marketable securities at year-end 2025 [#10-K-2026-02-24] [#IR-2026-02-24].
Posture
Constructive
Lead driver
Momentum
What changed
4 setup hits (3d) with net bullish as of 2026-06-01.
What can break
Corcept's 2025 net product revenue still came from its existing product base, so oncology-commercial traction must be demonstrated rather than assumed [#10-K-2026-02-24].
Momentum
94
Value
59
Sentiment
17
Setup hits (3d)
4 · Net Bullish
AI TargetsBase $50.00 · Bull $60.00 · Bear $34.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-05-29 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-22 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $65.40
Why
Momentum94 · Δ7d +1.2
Value59 · Δ7d -0.1
Sentiment17 · Δ7d -9.4
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
94
34% active weight
Current posture
7d trendFlat
Δ7d
+1.2
Δ21d
+8.7
Value
59
32% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.3
Sentiment
17
33% active weight
Current posture
7d trendSoftening
Δ7d
-9.4
Δ21d
-19.7
Why this grade
Composite grade B. Momentum 94.0 / Value 59.1 / Sentiment 17.1
Fundamentals (TTM)As of 2026-05-29
Fundamentals (TTM)
As of 2026-05-29
Market Cap
$7.46B
Beta
0.24
Shares Out
105.19M
P/E (TTM)
39.5
P/S (TTM)
4.96
P/FCF (TTM)
22.54
Rev YoY
+13.7%
EPS YoY
-60.3%
Gross Margin
+98.2%
Op Margin
+8.8%
Net Debt
-$385.15M
Current Ratio
3.14
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology